// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

DASL-HiCaP Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Tamim Niazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Real-world outcomes in advanced renal cancer patients treated with stereotactic radiosurgery for intracranial metastases.

Abiola Fatimilehin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

Bio-miR A prognostic microRNA-based signature for localized clear cell renal cell carcinoma.

Alvaro Pinto - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Pembrolizumab

Digital score of lymphocytic infiltration in tumor-associated stroma in relation to overall survival in bladder cancer.

Robert Jewsbury - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dental and Oral Health

Bladder Cancer

N/A

LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease Update with more than two years of follow-up data.

Eric Jonasch - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Defining more precisely the effects of docetaxel plus ADT for men with mHSPC Meta-analysis of individual participant data from randomized trials.

Claire Louise Vale - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Docetaxel

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Evan Y. Yu - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Androgen Tear

Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Shahneen Sandhu - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

CB-7598

Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC) Expanded efficacy analyses from KEYNOTE-564.

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Pembrolizumab

Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC) The JAVELIN Renal 101 experience.

Renee Maria Saliby - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Atezolizumab

A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer CREST Study Cohort B.

Neal D. Shore - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Transitional cell carcinoma of the bladder

stannous fluoride

LITESPARK-022 A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC).

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Clear cell renal carcinoma

Pembrolizumab

TALAPRO-3 A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).

Neeraj Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Brain metastasis

Enzalutamide

Combined Anterior Cruciate Ligament Repair and Anterolateral Ligament Internal Brace Augmentation: Minimum 2-Year Patient-Reported Outcome Measures

Graeme P. Hopper - American Orthopaedic Society for Sports Medicine (AOSSM) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Acute Effects of Increased Joint Mobilization Treatment Duration on Ankle Function and Dynamic Postural Control in Female Athletes With Chronic Ankle Instability

Christopher J. Holland - American Orthopaedic Society for Sports Medicine (AOSSM) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Systematic Review of Preinjury Mental Health Problems as a Vulnerability Factor for Worse Outcome After Sport-Related Concussion

Grant L. Iverson - American Orthopaedic Society for Sports Medicine (AOSSM) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sport-related concussion

N/A

Epidemiology of American Football Injuries at Universities in the United Kingdom

John M. Bayram - American Orthopaedic Society for Sports Medicine (AOSSM) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Surgical Repair of Distal Biceps Femoris Avulsion Injuries in Professional Athletes

Joshua W. Thompson - American Orthopaedic Society for Sports Medicine (AOSSM) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Dermatologic Adverse Events in Acute Myeloid Leukemia Patients Treated with IDH Inhibitors Ivosidenib and Enasidenib

Rose Parisi - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Acute myelocytic leukemia

Enasidenib

Primary Cutaneous Marginal Zone B-Cell Lymphoma Involution with Anetoderma

Ala Haqiqi - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Mucosa-associated lymphoid tissue lymphoma

Warfarin

Copyright © 2026. QuantiNova All rights reserved